* The report reviews current pipeline of Pharming
Group N.V.'s human therapeutic division and enlists all their major and minor projects
The US company licensed exclusive rights to commercialise Ruconest in North America for the treatment of acute attacks of HAE as well as other potential future indications from Pharming
. The Dutch company is also eligible to another USD-5-million milestone payment upon FDA acceptance of the BLA for review.
Shield monitors critical systems 24x7 and detects when unauthorized modifications are made to a website that could mean that it has been compromised.
In some Pharming
attacks, spyware or Trojan applications installed on end hosts have also been used to perform keystroke logging and Website redirection without the user being aware.
has also acquired patents on the production of recombinant protein products and production technology patents for proteins, fusion proteins, as well as peptides.
Group NV (Amsterdam:PHARM.AS) and Salix Pharmaceuticals (NasdaqGS:SLXP) on Monday jointly announced the introduction of RUCONEST (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg in the US for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema (HAE).
NORDIC BUSINESS REPORT-15 April 2010-Swedish Orphan Biovitrum, Pharming
in distribution deal for Rhucin(C)1994-2010 M2 COMMUNICATIONS http://www.m2.com
While phishing scams are still going strong, scammers are moving toward a more high-tech method of online fraud known as pharming
(Deforest, WI; 516-374-3031) a privately-held biotechnology company merging genomics and reproductive technologies to advance human health, announced the company had terminated its agreement with Pharming
Koivurinta served as vice president of Pharming
Biotech company Pharming
Group NV (Amsterdam:PHARM.AS) reported on Friday the execution of a EUR15.6m straight debt financing with Oxford Finance and Silicon Valley Bank (the lenders).
M2 PHARMA-April 18, 2013-Santarus Inc and Pharming
Group NV partnership submits RUCONEST's BLA to FDA(C)2013 M2 COMMUNICATIONS